Ramipril

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search

Synonyms / Brand Names: Altace, Tritace, Ramace

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884

Dosing and Administration

Heart Failure Post-MI

Adults

PO 2.5 mg twice daily. Switch to 1.25 mg twice daily if hypotension occurs. Titrate to target dose of 5 mg twice daily.

Hypertension

Adults

PO Initial dose is 2.5 mg every day initially. Maintenance dose is 2.5 to 20 mg/day as single dose or in 2 equally divided doses.

Patients with Renal Impairment

PO 1.25 mg every day in patients with Ccr below 40 mL/min (serum creatinine higher than 2.5 mg/dL; max, 5 mg/day).

Reduction in Risk of MI, Stroke, and Death from CV Causes

Adults

PO Initial dose is 2.5 mg every day for 1 wk, 5 mg every day for 3 wk, then increase the dose as tolerated to maintenance dose. Maintenance dose is 10 mg every day or in divided doses if patient is hypertensive or recently post-MI.



FDA Package Insert Resources
Indications, Contraindications, Side Effects, Drug Interactions, etc.

Calculate Creatine Clearance
On line calculator of your patients Cr Cl by a variety of formulas.

Convert pounds to Kilograms
On line calculator of your patients weight in pounds to Kg for dosing estimates.

Publication Resources
Recent articles, WikiDoc State of the Art Review, Textbook Information

Trial Resources
Ongoing Trials, Trial Results

Guidelines & Evidence Based Medicine Resources
US National Guidelines, Cochrane Collaboration, etc.

Media Resources
Slides, Video, Images, MP3, Podcasts, etc.

Patient Resources
Discussion Groups, Handouts, Blogs, News, etc.

International Resources
en Español






FDA Package Insert Resources

Indications

Contraindications

Side Effects

Drug Interactions

Precautions

Overdose

Instructions for Administration

How Supplied

Pharmacokinetics and Molecular Data

FDA label

FDA on Ramipril

Return to top

Publication Resources

Most Recent Articles on Ramipril

Review Articles on Ramipril

Articles on Ramipril in N Eng J Med, Lancet, BMJ

WikiDoc State of the Art Review

Textbook Information on Ramipril

Return to top

Trial Resources

Ongoing Trials with Ramipril at Clinical Trials.gov

Trial Results with Ramipril

Return to top

Guidelines & Evidence Based Medicine Resources

US National Guidelines Clearinghouse on Ramipril

Cochrane Collaboration on Ramipril

Cost Effectiveness of Ramipril

Return to top

Media Resources

Powerpoint Slides on Ramipril

Images of Ramipril

Podcasts & MP3s on Ramipril

Videos on Ramipril

Return to top

Patient Resources

Patient Information from National Library of Medicine

Patient Resources on Ramipril

Discussion Groups on Ramipril

Patient Handouts on Ramipril

Blogs on Ramipril

Ramipril in the News

Ramipril in the Marketplace

Return to top

International Resources

Ramipril en Español

Return to top


The content of this page is taken from the FDA package insert for this drug and should not be edited.

Personal tools